Cheng Guang-Shing, Campbell Angela P, Xie Hu, Stednick Zach, Callais Cheryl, Leisenring Wendy M, Englund Janet A, Chien Jason W, Boeckh Michael
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington; Pediatric Infectious Diseases, Seattle Children's Hospital, Seattle, Washington.
Biol Blood Marrow Transplant. 2016 May;22(5):925-31. doi: 10.1016/j.bbmt.2015.12.023. Epub 2015 Dec 31.
Early detection of subclinical lung function decline may help identify allogeneic hematopoietic cell transplant (HCT) recipients who are at increased risk for late noninfectious pulmonary complications, including bronchiolitis obliterans syndrome. We evaluated the use of handheld spirometry in this population. Allogeneic HCT recipients enrolled in a single-center observational trial performed weekly spirometry with a handheld spirometer for 1 year after transplantation. Participants performed pulmonary function tests in an outpatient laboratory setting at 3 time points: before transplantation, at day 80 after transplantation, and at 1 year after transplantation. Correlation between the 2 methods was assessed by Pearson and Spearman correlations; agreement was assessed using Bland-Altman plots. A total of 437 subjects had evaluable pulmonary function tests. Correlation for forced expiratory volume in 1 second (FEV1) was r = .954 (P < .0001) at day 80 and r = .931 (P < .0001) at 1 year when the handheld and laboratory tests were performed within 1 day of each other. Correlation for handheld forced expiratory volume in 6 seconds (FEV6) with laboratory forced vital capacity was r = .914 (P < .0001) at day 80 and r = .826 (P < .0001) at 1 year. The bias, or the mean difference (handheld minus laboratory), for FEV1 at day 80 and 1 year was -.13 L (limits of agreement, -.63 to .37) and -.10 L (limits of agreement, -.77 to .56), respectively. FEV6 showed greater bias at day 80 (-.51 L [limits of agreement, -1.44 to .42]) and 1 year (-.40 L [limits of agreement, -1.81 to 1.01]). Handheld spirometry correlated well with laboratory spirometry after allogeneic HCT and may be useful for self-monitoring of patients for early identification of airflow obstruction.
亚临床肺功能下降的早期检测可能有助于识别异基因造血细胞移植(HCT)受者中晚期非感染性肺部并发症风险增加的人群,包括闭塞性细支气管炎综合征。我们评估了在该人群中使用手持式肺活量测定法的情况。参与单中心观察性试验的异基因HCT受者在移植后1年内每周使用手持式肺活量计进行肺活量测定。参与者在门诊实验室环境中的3个时间点进行肺功能测试:移植前、移植后第80天和移植后1年。通过Pearson和Spearman相关性评估两种方法之间的相关性;使用Bland-Altman图评估一致性。共有437名受试者进行了可评估的肺功能测试。当手持式和实验室测试在彼此1天内进行时,移植后第80天1秒用力呼气量(FEV1)的相关性r = 0.954(P < 0.0001),1年时r = 0.931(P < 0.0001)。移植后第80天和1年时,手持式6秒用力呼气量(FEV6)与实验室用力肺活量的相关性分别为r = 0.914(P < 0.0001)和r = 0.826(P < 0.0001)。移植后第80天和1年时,FEV1的偏差或平均差异(手持式减去实验室)分别为-0.13 L(一致性界限,-0.63至0.37)和-0.10 L(一致性界限,-0.77至0.56)。FEV6在移植后第80天(-0.51 L[一致性界限,-1.44至0.42])和1年(-0.40 L[一致性界限,-1.81至1.01])时偏差更大。异基因HCT后手持式肺活量测定法与实验室肺活量测定法相关性良好,可能有助于患者自我监测以早期识别气流阻塞。